Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

380
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
380
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

462
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
462
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

217
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
217
Pharmacovigilance01:19

Pharmacovigilance

1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

206
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
206

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The Development and Use of Office of New Drugs Custom Medical Queries for Safety Analyses of Clinical Trial Data.

Drug safety·2025
查看所有相关文章

相关实验视频

Updated: Jan 8, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

监管决策中的替代终点

Linda J B Jeng1, Jeffrey Siegel2

  • 1Division of Biomedical Informatics, Research, and Biomarker Development, Office of Drug Evaluation Sciences, Office of New Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.

Clinical and translational science
|December 19, 2025
PubMed
概括

美国食品和药物管理局 (FDA) 需要有力的证据表明,药物可以改善患者的福祉,功能或生存. 用作替代终点 (SE) 的生物标志物可以加快针对未满足需求的新药的开发.

关键词:
生物标志物 生物标志物药物开发是药物的发展.替代终点的替代终点.

更多相关视频

Screening for Endocrine Activity in Water Using Commercially-available In Vitro Transactivation Bioassays
08:00

Screening for Endocrine Activity in Water Using Commercially-available In Vitro Transactivation Bioassays

Published on: December 4, 2016

7.9K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K

相关实验视频

Last Updated: Jan 8, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
Screening for Endocrine Activity in Water Using Commercially-available In Vitro Transactivation Bioassays
08:00

Screening for Endocrine Activity in Water Using Commercially-available In Vitro Transactivation Bioassays

Published on: December 4, 2016

7.9K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 临床研究 临床研究
  • 生物标志物 生物标志物

背景情况:

  • 药物的批准需要实质性的有效性证据.
  • 有效性必须证明患者的感觉,功能或生存状况有所改善.
  • 临床结果可以直接或间接地测量.

研究的目的:

  • 为了解释FDA对药物有效性的要求.
  • 突出替代终点 (SE) 在药物开发中的作用.
  • 强调生物标志物的潜力作为SEs.

主要方法:

  • 审查FDA的有效性要求.
  • 直接和间接结果测量的解释.
  • 讨论替代终点 (SE) 和生物标志物.

主要成果:

  • 美国食品和药物管理局要求药物批准有实质证据.
  • 通过患者报告的结果或代用终点 (SE) 来评估有效性.
  • 生物标志物可以作为有效的SEs.

结论:

  • 作为SE的生物标志物可以加速药物开发.
  • 这对于有未满足医疗需求的情况尤其重要.
  • 使用生物标志物作为SE与FDA的证据要求保持一致.